Paris Brain Institute aims to transform fundamental research results into tangible solutions that benefit patients in the field of brain health. A cornerstone of this approach is leveraging the power of entrepreneurship, notably through NeurAL, its acceleration program for innovative projects funded by an entrepreneurial philanthropy fund.

The second laureate, GlycaDX, is led by Dulce Papy-Garcia, a professor of biochemistry and glycoscience, and director of the “Cell Growth, Repair, and Tissue Regeneration” (Gly-CRRET) research unit at Paris-Est Créteil University (UPEC). The project, in link with ArrestAD research, aims to develop a drug candidate targeting the aggregation of abnormal tau proteins in neurons, a hallmark of Alzheimer’s disease.

https://parisbraininstitute.org/news/paris-brain-institute-announces-winners-second-edition-neural-its-acceleration-program-innovative-projects

ArrestAD project was initially scheduled to last 4 years (2017-2020), however, due to 1) COVID-19 sanitary crisis, 2) delay in tasks that required animals’ strains and human cells and 3) SCell termination, the consortium requested an amendment with no change to the maximum EU contribution to extend project duration until December 31^st, 2021 (M60).

In 2020, due to COVID-19 sanitary crisis the ArrestAD technical meeting was conduct online (Zoom, October 9^th and 10^th, 2020) with in addition to ArrestAD consortium members, members of the ArrestAD external and ethical advisory board, Prof. Guido David, Ms. Maï Panchal, and Pr. Paweł Łuków.